Although PD-1/PD-L1 blockade has achieved significant effects in clinical practice, the response rate in patients with nonselective non-small cell lung cancer is approximately 20%, and the response rate in patients with lung adenocarcinoma is even lower [5]. Here, CD274 is linked to lung adenocarcinoma.